Related Experiment Videos

The graft-versus-lymphoma effect: fact, fiction, or opportunity?

Michael R Bishop

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|September 10, 2003

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

The Lancet. Haematology·2026

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Leukemia·2026

Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis.

Blood advances·2026

Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).

Frontiers in oncology·2026

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

Cancer research communications·2026

See all related articles